Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7233MR)

This product GTTS-WQ7233MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7233MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6949MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ15167MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ15678MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ10865MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ962MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10843MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ1568MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ10385MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW